Search - tctmd.com

Displaying 61 - 80 of 127

Sort: Relevancy | Date

News Daily News

Olive Oil Consumption Linked to CVD Benefits in the US

Shelley Wood

March 09, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Yael L. Maxwell

January 16, 2020

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Statin Discontinuation in the Elderly Linked to More CV Events

Yael L. Maxwell

August 01, 2019

News Conference News SCCT 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Yael L. Maxwell

July 15, 2019

News Daily News

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Michael O'Riordan

March 27, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Atherosclerosis Features Differ Among Male Athletes From Different Sports

Todd Neale

February 18, 2019

News Daily News

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Shelley Wood

February 12, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Todd Neale

August 27, 2018

News Daily News

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Yael L. Maxwell

July 09, 2018

Advertisement

Olive Oil Consumption Linked to CVD Benefits in the US

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Statin Discontinuation in the Elderly Linked to More CV Events

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Atherosclerosis Features Differ Among Male Athletes From Different Sports

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content